01:57 PM EST, 01/17/2025 (MT Newswires) -- (Updates with responses from Bristol-Myers Squibb ( BMY ) and Boehringer Ingelheim in the eighth and ninth paragraphs.)

Novo Nordisk's ( NVO ) Ozempic, Wegovy and Rybelsus are among the 15 additional drugs selected for US Medicare price negotiations, the Department of Health and Human Services said Friday.

Novo Nordisk ( NVO ) shares were down over 5% in recent trading.

The other drugs subject to the talks are:

GSK's (GSK) Trelegy Ellipta

Pfizer's ( PFE ) Xtandi and Ibrance

Bristol-Myers Squibb's ( BMY ) Pomalyst

Boehringer Ingelheim's Ofev

AbbVie's ( ABBV ) and Ironwood Pharmaceuticals' ( IRWD ) Linzess

AstraZeneca's ( AZN ) Calquence

Teva Pharmaceutical Industries' ( TEVA ) Austedo and Austedo XR

Theravance Biopharma's ( TBPH ) and GSK's Breo Ellipta

Boehringer Ingelheim's and Eli Lilly's ( LLY ) Tradjenta

Salix Pharmaceuticals' Xifaxan

AbbVie's ( ABBV ) Vraylar

Merck's ( MRK ) Janumet and Janumet XR

Amgen's ( AMGN ) Otezla

"Novo Nordisk ( NVO ) remains opposed to government price setting through the [Inflation Reduction Act] and has significant concerns about how the law is being implemented by this administration," Novo Nordisk ( NVO ) said in a statement emailed to MT Newswires. "Even as our IRA lawsuit progresses, we remain committed to working with policymakers to advance solutions to ensure access and affordability for all patients."

GSK told MT Newswires it is aware that Breo and Trelegy were chosen for negotiation, adding that it is reviewing the latest announcement and is ready to work with the Centers for Medicare & Medicaid Services.

Teva told MT Newswires that CMS' decision is "truly disappointing" for patients with mental health conditions, movement disorders and limited treatment options. "Arbitrary price setting creates unnecessary barriers and disruptions to treatment access," Teva said. "We will continue to work with the government toward our shared goal of increasing access to affordable medicines."

Ironwood Pharmaceuticals ( IRWD ) told MT Newswires it has nothing further to add right now.

"We maintain our position that the price-setting portion of the IRA is deeply flawed," Bristol-Myers Squibb ( BMY ) said in a statement emailed to MT Newswires. "The government price setting process has not solved the real barriers to patient access and affordability, instead overlooking the biggest problem in patient affordability: how plans determine patient out-of-pocket costs."

Boehringer Ingelheim told MT Newswires that "Tradjenta has not been part of the Lilly alliance for a few years now." On the CMS' decision, Boehringer Ingelheim said "government price setting will do little to actually help patients at the pharmacy counter," but added that it remains committed to holding discussions with CMS.

The other companies didn't immediately respond to requests for comment from MT Newswires.

Price: 78.39, Change: -4.68, Percent Change: -5.63